Therapeutic Strategies for SARS-CoV-2 acting on ACE-2.
作者信息
Vitiello A, Ferrara F
机构信息
Clinical Pharmacologist, Pharmaceutical department, Usl Umbria 1, A.Migliorati street, 06132, Perugia, Italy.
Hospital Pharmacist Manager, Pharmaceutical department, Usl Umbria 1, A.Migliorati street, 06132, Perugia, Italy.
出版信息
Eur J Pharm Sci. 2021 Jan 1;156:105579. doi: 10.1016/j.ejps.2020.105579. Epub 2020 Sep 30.
Abstract
摘要
相似文献
1
Therapeutic Strategies for SARS-CoV-2 acting on ACE-2.作用于血管紧张素转换酶2（ACE-2）的新型冠状病毒2（SARS-CoV-2）治疗策略
Eur J Pharm Sci. 2021 Jan 1;156:105579. doi: 10.1016/j.ejps.2020.105579. Epub 2020 Sep 30.
2
The renin-angiotensin system and specifically angiotensin-converting enzyme 2 as a potential therapeutic target in SARS-CoV-2 infections.肾素-血管紧张素系统，特别是血管紧张素转换酶 2 作为 SARS-CoV-2 感染的潜在治疗靶点。
Naunyn Schmiedebergs Arch Pharmacol. 2021 Jul;394(7):1589-1593. doi: 10.1007/s00210-021-02108-z. Epub 2021 Jun 21.
3
Drugs acting on the renin-angiotensin system and SARS-CoV-2.作用于肾素-血管紧张素系统的药物与 SARS-CoV-2。
Drug Discov Today. 2021 Apr;26(4):870-874. doi: 10.1016/j.drudis.2021.01.010. Epub 2021 Jan 21.
4
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology.下调膜结合血管紧张素转换酶 2（ACE2）受体在 COVID-19 免疫病理中起关键作用。
Curr Drug Targets. 2021;22(3):254-281. doi: 10.2174/1389450121666201020154033.
5
Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.血管紧张素转换酶 2 和肾素血管紧张素系统抑制剂在 COVID-19 中的应用：最新进展。
High Blood Press Cardiovasc Prev. 2021 Mar;28(2):129-139. doi: 10.1007/s40292-021-00439-9. Epub 2021 Feb 26.
6
Scientific Hypothesis for Treatment of COVID-19's Lung Lesions by Adjusting ACE/ACE2 Imbalance.调整 ACE/ACE2 失衡治疗 COVID-19 肺部病变的科学假说。
Cardiovasc Toxicol. 2021 Jun;21(6):498-503. doi: 10.1007/s12012-021-09649-y. Epub 2021 Apr 9.
7
Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.通过药物文库的体外筛选鉴定 SARS-CoV-2 受体结合抑制剂。
Molecules. 2021 May 27;26(11):3213. doi: 10.3390/molecules26113213.
8
Elovanoids downregulate SARS-CoV-2 cell-entry, canonical mediators and enhance protective signaling in human alveolar cells.Elovanoids 下调 SARS-CoV-2 细胞进入、经典介质并增强人肺泡细胞的保护信号。
Sci Rep. 2021 Jun 10;11(1):12324. doi: 10.1038/s41598-021-91794-z.
9
Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).抑制 S 蛋白 RBD 和 hACE2 相互作用以控制 SARS-CoV-2 感染（COVID-19）。
Mini Rev Med Chem. 2021;21(6):689-703. doi: 10.2174/1389557520666201117111259.
10
An update on ACE2 amplification and its therapeutic potential.ACE2 扩增及其治疗潜力的最新进展。
Acta Physiol (Oxf). 2021 Jan;231(1):e13513. doi: 10.1111/apha.13513. Epub 2020 Jun 17.
引用本文的文献
1
Recent advances in COVID-19-induced liver injury: causes, diagnosis, and management.新型冠状病毒肺炎相关肝损伤的研究进展：病因、诊断与治疗。
Inflammopharmacology. 2024 Oct;32(5):2649-2680. doi: 10.1007/s10787-024-01535-7. Epub 2024 Aug 10.
2
Effects of Vitamin D on the Renin-Angiotensin System and Acute Childhood Pneumonia.维生素D对肾素-血管紧张素系统及儿童急性肺炎的影响
Antibiotics (Basel). 2022 Nov 3;11(11):1545. doi: 10.3390/antibiotics11111545.
3
Overview of pharmacotherapy targeting COVID-19 disease based on ACE-2: current challenges and future directions.基于 ACE-2 的 COVID-19 疾病药物治疗概述：当前的挑战和未来的方向。
Herz. 2023 Oct;48(5):372-375. doi: 10.1007/s00059-022-05142-6. Epub 2022 Nov 4.
4
In Silico Molecular Dynamics of Griseofulvin and Its Derivatives Revealed Potential Therapeutic Applications for COVID-19.灰黄霉素及其衍生物的计算机分子动力学揭示了其在 COVID-19 治疗中的潜在应用。
Int J Mol Sci. 2022 Jun 21;23(13):6889. doi: 10.3390/ijms23136889.
5
Pharmacotherapy Based on ACE2 Targeting and COVID-19 Infection.基于 ACE2 靶向和 COVID-19 感染的药物治疗。
Int J Mol Sci. 2022 Jun 14;23(12):6644. doi: 10.3390/ijms23126644.
6
Renin Angiotensin System and COVID-19 Infection.肾素-血管紧张素系统与新型冠状病毒肺炎感染
Adv Pharm Bull. 2022 Jan;12(1):1-4. doi: 10.34172/apb.2022.001. Epub 2021 Jan 23.
7
Pregnancy and COVID-19, focus on vaccine and pharmacological treatment.妊娠与 COVID-19，关注疫苗和药物治疗。
J Reprod Immunol. 2022 Jun;151:103630. doi: 10.1016/j.jri.2022.103630. Epub 2022 Apr 21.
8
Modified mRNA-Based Vaccines Against Coronavirus Disease 2019.基于修饰信使 RNA 的 2019 年冠状病毒病疫苗。
Cell Transplant. 2022 Jan-Dec;31:9636897221090259. doi: 10.1177/09636897221090259.
9
Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.COVID-19患者肺纤维化状态的病理生理学及治疗前景
Curr Res Pharmacol Drug Discov. 2021;2:100056. doi: 10.1016/j.crphar.2021.100056. Epub 2021 Sep 16.
10
Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.巴瑞替尼/瑞德西韦治疗成人 COVID-19 感染的关联观点。
Mol Biol Rep. 2022 Jan;49(1):827-831. doi: 10.1007/s11033-021-06888-8. Epub 2021 Nov 27.
本文引用的文献
1
Correlation between renin-angiotensin system and Severe Acute Respiratory Syndrome Coronavirus 2 infection: What do we know?肾素-血管紧张素系统与严重急性呼吸综合征冠状病毒 2 感染的相关性：我们了解多少？
Eur J Pharmacol. 2020 Sep 15;883:173373. doi: 10.1016/j.ejphar.2020.173373. Epub 2020 Jul 15.
2
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?吡非尼酮在抗击由 SARS-CoV-2 引起的炎症和纤维化状态中的附加价值：抗炎和抗纤维化治疗能否解决感染的肺部并发症？
Eur J Clin Pharmacol. 2020 Nov;76(11):1615-1618. doi: 10.1007/s00228-020-02947-4. Epub 2020 Jun 27.
3
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.血管紧张素转化酶抑制剂改善合并高血压的 COVID-19 患者的临床结局。
Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.
4
Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms.新型冠状病毒（COVID-19）感染中枢神经系统的证据：组织分布、宿主-病毒相互作用及潜在神经嗜性机制。
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998. doi: 10.1021/acschemneuro.0c00122. Epub 2020 Mar 13.
5
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2（ACE2）作为严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的受体：分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
6
Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.冠状病毒刺突蛋白和宿主 ACE2 受体的组成和分化预测了 SARS-CoV-2 的潜在中间宿主。
J Med Virol. 2020 Jun;92(6):595-601. doi: 10.1002/jmv.25726. Epub 2020 Mar 11.
7
Efficiency and specificity of RAAS inhibitors in cardiovascular diseases: how to achieve better end-organ protection?RAAS 抑制剂在心血管疾病中的疗效和特异性：如何实现更好的靶器官保护？
Hypertens Res. 2017 Nov;40(11):903-909. doi: 10.1038/hr.2017.65. Epub 2017 Jul 6.
8
Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy.组织肾素-血管紧张素-醛固酮系统：药物治疗的靶点。
Annu Rev Pharmacol Toxicol. 2010;50:439-65. doi: 10.1146/annurev.pharmtox.010909.105610.
9
Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.盐皮质激素受体阻滞剂可增加充血性心力衰竭患者的血管紧张素转换酶2活性。
Circ Res. 2005 Oct 28;97(9):946-53. doi: 10.1161/01.RES.0000187500.24964.7A. Epub 2005 Sep 22.
10
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.血管紧张素转换酶抑制和血管紧张素II受体阻滞剂对心脏血管紧张素转换酶2的影响。
Circulation. 2005 May 24;111(20):2605-10. doi: 10.1161/CIRCULATIONAHA.104.510461. Epub 2005 May 16.
Zotero 插件